Can a Reverse Split Revive Tilray’s Faltering Stock?

Tilray Brands, Inc. has initiated a drastic corporate action in a bid to halt its precipitous stock decline. The cannabis giant executed a 1-for-10 reverse stock split, a move compelled by its struggle to maintain compliance with Nasdaq listing requirements and to present a more stable equity profile to the market.

A Technical Lifeline for Listing Compliance

The primary catalyst for this reverse split was the Nasdaq’s mandate that listed companies maintain a minimum bid price of $1 per share. With Tilray’s stock having traded persistently below this critical threshold, the company’s management viewed the consolidation as a necessary step to preserve its exchange listing. The action, effective at the start of trading on December 2, 2025, reduced the number of outstanding shares from approximately 1.16 billion to about 116 million on a split-adjusted basis.

Beyond mere compliance, the leadership hopes this technical adjustment will yield additional benefits. An optically higher share price could potentially make the stock more appealing to institutional investors and certain funds that have minimum price thresholds. The company also anticipates administrative cost savings associated with having a reduced share count.

Precipitous Decline Sets the Stage

The need for such emergency measures was underscored by a period of severe underperformance. In the month preceding the split, Tilray’s shares plummeted nearly 40%, a stark contrast to the broader medical cannabis sector, which managed to post gains during the same timeframe. Even compared to the stable S&P 500, Tilray’s performance was deeply negative. The most recent trading session offered no respite, with the stock shedding another four percent, cementing its position in a pronounced downtrend.

Should investors sell immediately? Or is it worth buying Tilray?

All Eyes on January Earnings

Investor attention now shifts to a pivotal upcoming event: the release of Tilray’s quarterly financial results on January 8, 2026. This report is seen as a crucial test of the company’s underlying health beyond technical maneuvers. Market analysts have established the following consensus expectations for the announcement:

• Earnings Per Share (EPS): -$0.02 (an 80% improvement year-over-year)
• Revenue: $209.65 million (a slight decrease of 0.62%)
• Full-Year Revenue Forecast: $867.01 million (representing 5.56% growth)
• Full-Year EPS Forecast: -$0.05

While the previous first fiscal quarter showed a five percent revenue increase and net income of $1.5 million, concerning weaknesses were evident beneath the surface. The beverage segment has emerged as a particular soft spot, with sales declining and gross profit falling by almost seven percent in that division.

Furthermore, Tilray missed its own revenue targets for fiscal year 2025, after having already been forced to lower its guidance the previous April. Structural challenges continue to loom large: the absence of federal legalization in the United States significantly hampers growth prospects, while the company’s diversification into alcohol and wellness segments faces intense competitive pressure. The January 8th report will reveal whether Tilray can demonstrate fundamental progress or if investors are in for another disappointment.